A small accelerator born at the Francis Crick Institute is helping UK start-ups in bioconvergence find investors who “speak their language,” according to Venture Capital Journal. Venture Capital Journal published the article, titled “Filling a funding gap in UK bioconvergence,” on 1 September 2026, and credited it to David Bogoslaw, according to Venture Capital Journal.
Accelerator origins at the Francis Crick Institute
The article describes “a small accelerator born at the Francis Crick Institute,” according to Venture Capital Journal. Venture Capital Journal frames the accelerator’s role as helping UK start-ups identify investors who understand the relevant domain “language,” according to Venture Capital Journal.
Focus on bioconvergence and a UK funding gap
Venture Capital Journal characterizes the situation as “filling a funding gap in UK bioconvergence,” according to Venture Capital Journal. The piece specifically links the accelerator’s work to UK start-ups and investor matching in the context of bioconvergence, according to Venture Capital Journal.
Publication details and access
The Venture Capital Journal page lists tags including AI, Healthcare, Life Sciences, Technology, and UK, according to Venture Capital Journal. The page indicates that readers must “Create an account to continue reading” and offers registration for access, according to Venture Capital Journal.
Context (widely known)
Bioconvergence is widely known as the intersection of biology with fields such as engineering and computing, and it is often discussed alongside areas like AI and healthcare. Accelerators are widely known as programs that help early-stage companies by providing structured support and introductions to investors.
